Changes in the Predicted Adult Height after Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Idiopathic True Precocious Puberty

Kwon, Eun Byul; Lee, Seung Joon; Cha, Minah; Kim, Se Young

doi:10.6065/apem.2012.17.3.160

Cited by 8 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, in the treatment of girls with ICPP, the efficacy and safety of domestic leuprorelin were comparable with imported leuprorelin. The results of this study were consistent with reported results[ 22 23 24 25 ] in literature, provided a reference for the clinical treatment of ICPP. Domestic leuprorelin may safely and effectively used in the treatment of ICPP, is worthy of clinical application and promotion.…”

Section: Discussionsupporting

confidence: 93%

Efficacy and Safety of Domestic Leuprorelin in Girls with Idiopathic Central Precocious Puberty

Gong

Guo³

et al. 2015

Chinese Medical Journal

View full text Add to dashboard Cite

Background:In central precocious puberty (CPP), the pulse secretion and release of gonadotropin-releasing hormone (GnRH) are increased due to early activation of the hypothalamic-pituitary-gonadal axis, resulting in developmental abnormalities with gonadal development and appearance of secondary sexual characteristics. The CPP without organic disease is known as idiopathic CPP (ICPP). The objective of the study was to evaluate the clinical efficacy and safety of domestic leuprorelin (GnRH analog) in girls with ICPP.Methods:A total of 236 girls with ICPP diagnosed from April 2012 to January 2014 were selected and were randomized into two groups. One hundred fifty-seven girls in the test group were treated with domestic leuprorelin acetate, 79 girls in the control group were treated with imported leuprorelin acetate. They all were treated and observed for 6 months. After 6-month treatment, the percentage of children with peak luteinizing hormone (LH) ≤3.3 U/L, the percentage of children with peak LH/peak follicle stimulating hormone (FSH) ratio <0.6, the improvements of secondary sexual characteristics, gonadal development and sex hormone levels, the change of growth rate of bone age (BA) and growth velocity, and drug adverse effects between two groups were compared.Results:After the treatment, the percentage of children with a suppressed LH response to GnRH, defined as a peak LH ≤3.3 U/L, at 6 months in test and control groups were 96.80% and 96.20%, respectively, and the percentage of children with peak LH/FSH ratio ≤0.6 at 6 months in test and control groups were 93.60% and 93.70%, respectively. The sizes of breast, uterus and ovary of children and the levels of estradiol (E2) were significantly reduced, and the growth rate of BA was also reduced. All the differences between pre- and post-treatment in each group were statistically significant (P < 0. 05), but the differences of the parameters between two groups were not significant (P > 0.05).Conclusions:Domestic leuprorelin is effective and safe in the treatment of Chinese girls with ICPP. Its effectiveness and safety are comparable with imported leuprorelin.

show abstract

Section: Discussionsupporting

confidence: 93%

Efficacy and Safety of Domestic Leuprorelin in Girls with Idiopathic Central Precocious Puberty

Gong

Guo³

et al. 2015

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

“…Kwon et al . ( 16 ) reported that the PAH increased by approximately 5 cm in 2 yr and approximately 6–7 cm in 3 yr after treatment. Another study ( 4 ) showed that NFH increased by approximately 5.1 cm in 71 CPP patients who started treatment at 8.5 yr of age.…”

Section: Discussionmentioning

confidence: 98%

Age at menarche and near final height after treatment with gonadotropin-releasing hormone agonist alone or combined with growth hormone in Korean girls with central precocious puberty

Gyon

Yun

Kim

et al. 2015

Clin Pediatr Endocrinol

View full text Add to dashboard Cite

Abstract.The use of a GnRH agonist (GnRHa) in central precocious puberty (CPP) is known to slow puberty progression, subsequently prevent early menarche, and attenuate the height loss caused by advanced skeletal maturation. But enhancing the final height has been so controversial that an additional approach has been used. We investigated the menarcheal age and near final height (NFH) in girls with CPP treated with GnRHa (N = 61) or GnRHa combined GH (N = 24). GnRHa was started at 8.1 ± 0.7 yr and administered for 2.1 ± 1.0 years. GH was used for 2.1 ± 1.1 yr in subjects with a short predicted adult height (PAH). Menarche occurred at 11.6 ± 0.8 yr of age, which was 15.7 ± 6.4 mo after GnRHa discontinuation. PAH increased significantly from 152.0 ± 7.2 cm to 158.8 ± 5.6 cm during treatment, and the NFH (159.7 ± 4.8 cm) was taller than the midparental height (157.8 ± 3.4 cm). The combined treatment group showed a greater height increment during treatment. Younger age, taller height at the start of treatment, taller parental height and longer duration of treatment were the factors influencing NFH. In conclusion, GnRHa treatment in girls with CPP could improve NFH and delay menarche close to the general population. If GnRHa combined with GH is used in girls with CPP and a short midparental height, it would improve the NFH to a value similar to that in the general population.

show abstract

“…As central precocious puberty leads to early menarche, treatment is necessary to stop or prevent regular cyclical menstruation. Moreover, gonadotropin-releasing hormone analog treatment is used to promote increase in height because early skeletal maturation in this condition diminishes the final adult height 3) . Women who experience very early puberty, for example, precocious puberty or menarche earlier than the average age, are known to be at a greater risk of psychosocial problems 4) such as delinquency and risky sexual behavior, as well as physical health problems 5 6 7 8) such as obesity, diabetes, cardiovascular disease, and breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Effects of early menarche on physical and psychosocial health problems in adolescent girls and adult women

Yoo

2016

Korean J Pediatr

View full text Add to dashboard Cite

The menarcheal age of Korean women has been rapidly decreasing for the last 50 years, and the average menarcheal age of women born in the 1990s is approaching 12.6 years. In addition, interest in early puberty has been increasing recently owing to the rapid increase in precocious puberty. Generally, out of concern for short stature and early menarche, idiopathic central precocious puberty in female adolescents is treated with gonadotropin-releasing hormone analogs. Studies to date have described the association between early menarche and psychosocial problems such as delinquency and risky sexual behavior, as well as physical health problems such as obesity, diabetes, cardiovascular diseases, and breast cancer throughout the lifespan of women. However, the pathophysiological mechanism underlying this association has not been clarified thus far. In this article, we review and discuss the existing literature to describe the current understanding of the effects of early menarche on the physical and psychosocial health of adolescent girls and adult women.

show abstract

Changes in the Predicted Adult Height after Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Idiopathic True Precocious Puberty

Cited by 8 publications

References 19 publications

Efficacy and Safety of Domestic Leuprorelin in Girls with Idiopathic Central Precocious Puberty

Efficacy and Safety of Domestic Leuprorelin in Girls with Idiopathic Central Precocious Puberty

Age at menarche and near final height after treatment with gonadotropin-releasing hormone agonist alone or combined with growth hormone in Korean girls with central precocious puberty

Effects of early menarche on physical and psychosocial health problems in adolescent girls and adult women

Contact Info

Product

Resources

About